Relationship between the expression of MDR1 in hepatocellular cancer and its biological behaviors.
OBJECTIVE
By the detection of HBV infection, AFP and AST, the targets of biological behavior and the gene expression of multi-drug resistance gene 1 (MDR1) in hepatocellular carcinoma (HCC), we investigate characteristics of the expression of MDR1 in HCC and its relationship with HCC biological behavior.


METHODS
Using real-time fluorescence quantitative PCR (FQ-PCR) to detect the expressions of MDR1 in 102 samples of HCC tissue and 20 samples of non-cancerous tissue, we analyze the relationship between expressions of MDR1 and biological characteristics of HCC.


RESULTS
The expression of MDR1 in HCC is 0.55 ± 0.27, and in normal liver tissues is 0.23 ± 0.10, respectively. The expression in HCC is higher than it in normal liver tissue, the difference is statistically significant (P<0.05) and the difference between the expression and the HCC envelopes is statistically significant, and the expression increases along with the increase of Edmondson classification (P<0.05). HBV infection, AFP positive, the rise of AST, all these factors have positive correlations with the expression (r=0.463, 0.473, 0.299). In MDR1 expressions of HCC patients, the survival curve of the negative is higher than that of the positive, but the difference is not statistically significant.


CONCLUSIONS
There are drug resistance phenomena in HCC, MDR1 expression may play an important role in primary HCC drug resistance. HBV infection can be detected as a reference indicator of HCC chemotherapy resistance, plasma levels of AFP, AST can be used as a reference index change dynamic monitoring of MDR1 expression.
Department of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China.
Bo
B
Gao
Department of Obstetrics and Gynecology, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China.
Feng-Mei
FM
Yang
Department of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China.
Zong-Tao
ZT
Yu
Department of Infection Control, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China.
Rui
R
Li
Department of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China.
Fei
F
Xie
Department of Cardiology, Jiangyan District Third People's Hospital Taizhou 225500, Jiangsu China.
Jie
J
Chen
Department of Laboratory Medicine, The Hospital of Traditional Chinese Medicine Shiyan 442000, Hubei, China.
Hai-Jun
HJ
Luo
Department of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China.
Ji-Cai
JC
Zhang
D018435:ATP Binding Cassette Transporter, Subfamily B / Q000235:genetics; D000368:Aged; D001219:Aspartate Aminotransferases / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000821:virology; D016022:Case-Control Studies; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006509:Hepatitis B / Q000150:complications / Q000821:virology; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D012307:Risk Factors; D015854:Up-Regulation; D000509:alpha-Fetoproteins / Q000032:analysis
C513055:ABCB1 protein, human; C097353:AFP protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D000509:alpha-Fetoproteins; D001219:Aspartate Aminotransferases
AFP; HBV infection; MDR1 gene; expression; hepatocellular carcinoma